In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5717-5720

  Tang, Hung Jen ^a,d   Chen, Chi Chung ^a,c   Cheng, Kuo Chen ^a   Wu, Kuan Ying ^a   Lin, Yi Chung ^a   Zhang, Chun Cheng ^a   Weng, Tzu Chieh ^a   Yu, Wen Liang ^a   Chiu, Yu Hsin ^a   Toh, Han Siong ^a   Chiang, Shyh Ren ^a   Su, Bo An ^a   Ko, Wen Chien ^b   Chuang, Yin Ching ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b Institutes of Biotechnology   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; FUSIDIC ACID; LINEZOLID; MINOCYCLINE; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; ORGANOPHOSPHONATES; OXAZOLIDINONES; PEPTIDES, CYCLIC; RIFAMPIN; STEROLS; TETRACYCLINES;

EID: 84885920711     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01236-13     Document Type: Article

References (20)

1. Prince AS. 2002. Biofilms, antimicrobial resistance, and airway infection. N. Engl. J. Med. 347:1110-1111.
2. Edmiston CE, Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, Towne JB. 2006. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am. J. Surg. 192:344-354.
3. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55. doi:10.1093/cid/ciq146.
5. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660.
6. Chung M, de Lencastre H, Matthews P, Tomasz A, Adamsson I, Aires de Sousa M, Camou T, Cocuzza C, Corso A, Couto I, Dominguez A, Gniadkowski M, Goering R, Gomes A, Kikuchi K, Marchese A, Mato R, Melter O, Oliveira D, Palacio R, Sa-Leao R, Santos Sanches I, Song JH, Tassios PT, Villari P. 2000. Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains. Microb. Drug Resist. 6:189-198.
7. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
8. Tang HJ, Chen CC, Cheng KC, Toh HS, Su BA, Chiang SR, Ko WC, Chuang YC. 2012. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J. Antimicrob. Chemother. 67:944-950.
9. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. CLSI, Wayne, PA.
10. Andrews JM. 2013. BSAC methods for antimicrobial susceptibility testing. (Version 12). British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom. http://www.bsac.org.uk/Susceptibility-Testing/Breakpoints.
11. Brown SD, Traczewski MM. 2007. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J. Clin. Microbiol. 45:2173-2179.
12. Wu WS. 2013. Efficacy of combination oral antimicrobial agnents against biofilm-embedded methicillin-resistant Staphyococcus aureus. J. Microbiol. Immunol. Infect. 46:89-95.
13. Tang HJ, Chen CC, Ko WC, Yu WL, Chiang SR, Chuang YC. 2011. In vitro efficacy of antimicrobial agents against high-inoculum or biofilmembedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 mug/mL (VA2-MRSA). Int. J. Antimicrob. Agents 38:46-51.
14. Ju O, Woolley M, Gordon D. 2006. Emergence and spread of rifampicinresistant, methicillin-resistant Staphylococcus aureus during vancomycinrifampicin combination therapy in an intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 25:61-62.
15. Miró JM, García-de-la-MàriaC Armero Y, Soy D, Moreno A, del Río A, Almela M, Sarasa M, Mestres CA, Gatell JM, Jiménez de Anta MT, Marco F; Hospital Clinic Experimental Endocarditis Study Group. 2009. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin- resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4172-4177.
16. Howden BP, Grayson ML. 2006. Dumb and dumber -the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 42:394-400.
17. Ferry T, Uckay I, Vaudaux P, Francois P, Schrenzel J, Harbarth S, Laurent F, Bernard L, Vandenesch F, Etienne J, Hoffmeyer P, Lew D. 2010. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur. J. Clin. Microbiol. Infect. Dis. 29:171-180.
18. Matthews PC, Berendt AR, McNally MA, Byren I. 2009. Diagnosis and management of prosthetic joint infection. BMJ 338:b1773. doi:10.1136/bmj.b1773.
19. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
20. O'Neill AJ, Cove JH, Chopra I. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J. Antimicrob. Chemother. 47:647-650.